Results 141 to 150 of about 641,238 (306)

Involvement of increased arginase-1 group 2 innate lymphoid cells and myeloid-derived suppressor cells in endometrial carcinoma: A pilot study

open access: yesJournal of International Medical Research
Background Endometrial carcinoma is a prevalent gynecologic malignancy with a relatively low survival rate. Emerging studies have demonstrated that crosstalk between group 2 innate lymphoid cells (ILC2s) and myeloid-derived suppressor cells drives tumor ...
Zhangyun Gong   +12 more
doaj   +1 more source

Measurement of suppressor transfer RNA activity. [PDF]

open access: yes, 1983
journal articleTransfer RNA (tRNA) suppression of nonsense mutations in prokaryotic systems has been widely used to study the structure and function of different prokaryotic genes.
Young, James F.; Laski, Frank A.; RajBhandary, Uttam L.; Sharp PA; Palese P   +1 more
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

open access: yesMolecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang   +9 more
wiley   +1 more source

Networks of tumor suppressors [PDF]

open access: yesThe EMBO Reports, 2000
M, Serrano, J, Massagué
openaire   +2 more sources

Tumor suppressor genes [PDF]

open access: yes
A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to the activating mutations that generate oncogenic alleles from proto-oncogene precursors, tumor suppressor genes, and the proteins they encode,
حسینی اصل, سید سعید
core  

Home - About - Disclaimer - Privacy